Evaluation of drug-specific multigene markers to predict aromatase inhibitor efficacy in advanced breast cancer: a cohort study from Danish Breast Cancer Cooperative Group

Autor: Ida Kappel Buhl, Troels Dreier Christensen, Anna Sofie Kappel Buhl, Ib Jarle Christensen, Eva Balslev, Ann Søegaard Knop, Bent Ejlertsen, Iben Kümler, Hella Danø, Adam Andrzej Luczak, Sven Tyge Langkjer, Søren Linnet, Erik Hugger Jakobsen, Jurij Bogovic, Vesna Glavicic, Ulla Hald Buhl, Steen Knudsen, Peter Buhl Jensen, Dorte Nielsen

Background Even with positive oestrogen receptor (ER+) status some advanced breast cancer (ABC) patients fail to benefit from endocrine therapy (ET). A method that previously predicted other drugs in various cancers was evaluated. Here multigene mark

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f74f0164074f9f5c285dc7b7b2cb16b
https://doi.org/10.21203/rs.2.10981/v1

Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort:a retrospective-prospective blinded study

Autor: Troels Dreier Christensen, Anna Sofie Kappel Buhl, Jurij Bogovic, Knud Mejer Nelausen, Ib Jarle Christensen, Eva Harder Brix, Ann Knoop, Else Svensson, Steen Knudsen, Sven Tyge Langkjer, Søren Linnet, Adam Luczak, Anker Jon Hansen, Peter Buhl Jensen, Eva Balslev, Erik Jakobsen, Dorte Nielsen, Bent Ejlertsen, Annie Rasmussen, Vesna Glavicic

Publikováno v: Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391-400 . https://doi.org/10.1007/s10549-018-4918-4
Buhl, A S K, Christensen, T D, Christensen, I J, Nelausen, K M, Balslev, E, Knoop, A S, Brix, E H, Svensson, E, Glavicic, V, Luczak, A, Langkjer, S T, Linnet, S, Jakobsen, E H, Bogovic, J, Ejlertsen, B, Rasmussen, A, Hansen, A, Knudsen, S, Nielsen, D & Jensen, P B 2018, ' Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort : a retrospective-prospective blinded study ', Breast Cancer Research and Treatment, vol. 172, no. 2, pp. 391–400 . https://doi.org/10.1007/s10549-018-4918-4
Breast Cancer Research and Treatment

PURPOSE: Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epiru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f4d0f127f0dafb654c610d7a725c80a
https://curis.ku.dk/portal/da/publications/predicting-efficacy-of-epirubicin-by-a-multigene-assay-in-advanced-breast-cancer-within-a-danish-breast-cancer-cooperative-group-dbcg-cohort(d94324d4-b6ee-484b-9f67-4ebcfeaf6560).html

Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort

Autor: Jurij Bogovic, Eva Harder Brix, Knud Mejer Nelausen, Dorte Nielsen, Troels Dreier Christensen, Vesna Glavicic, Bent Ejlertsen, Eva Balslev, Ann Knoop, Anna Sofie Kappel Buhl, Adam Luczak, Sven Tyge Langkjer, Peter Buhl Jensen, Steen Knudsen, Anker Jon Hansen, Else Svensson, Erik Jakobsen, Soeren Linnet, Ib Jarle Christensen, Annie Rasmussen

Publikováno v: Journal of Clinical Oncology. 35:1071-1071

1071 Background: Epirubicin remains a cornerstone in the treatment of primary and advanced breast cancer. This study evaluated the predictive effect of a multigene mRNA-based Drug Response Predictor (DRP) in the treatment of advanced breast cancer (A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56761e82b70645a06b49583f267a536d
https://doi.org/10.1200/jco.2017.35.15_suppl.1071

Fulvestrant response prediction from transcriptome data obtained from primary breast cancer biopsies

Autor: Peter Buhl Jensen, Eva Balslev, Anker Jon Hansen, Ann Knoop, Ulla Hald Buhl, Ib Jarle Christensen, Troels Dreier Christensen, Knud Mejer Nelausen, Peter Michael Vestlev, Nils Brünner, Steen Knudsen, Annie Rasmussen, Anna Sofie Kappel Buhl, Niels Henrik Hollander, Bent Ejlertsen, Eva Harder Brix, Dorte Nielsen

Publikováno v: Journal of Clinical Oncology. 34:e12056-e12056

e12056Background: Fulvestrant is a highly selective estrogen receptor (ER) antagonist used in the treatment of postmenopausal patients with ER-positive advanced breast cancer. To identify patients ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb8e79f9088f154744d7e5ed55e23405
https://doi.org/10.1200/jco.2016.34.15_suppl.e12056